Literature DB >> 11745432

C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors.

P Ioannidis1, T Trangas, E Dimitriadis, M Samiotaki, I Kyriazoglou, C M Tsiapalis, C Kittas, N Agnantis, F C Nielsen, J Nielsen, J Christiansen, N Pandis.   

Abstract

Mouse coding region determinant-binding (mCRD-BP) and human IGF-II mRNA-binding 1 (hIMP-1) proteins are orthologous mRNA-binding proteins that recognize c-myc and IGF-II mRNA, respectively, and regulate their expression posttranscriptionally. Here, we confirm that human CRD-BP/IMP-1 binds to c-myc mRNA and that it is predominantly expressed in fetal tissues. Moreover, hCRD-BP/IMP-1 expression was detected in cell lines of neoplastic origin and in selected primary tumors. In a series of 33 malignant and 10 benign mesenchymal tumors, 73% and 40%, respectively, were found to express hCRD-BP/IMP-1. In particular, expression was significant in 14 Ewing's sarcomas, all of which were positive. The data suggest that hCRD-BP/IMP-1 plays a role in abnormal cell proliferation in mesenchymal tumors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745432     DOI: 10.1002/ijc.1512

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

2.  Developmental and regional expression and localization of mRNAs encoding proteins involved in RNA translocation.

Authors:  Shabana Islam; Robert K Montgomery; John J Fialkovich; Richard J Grand
Journal:  J Histochem Cytochem       Date:  2005-07-11       Impact factor: 2.479

3.  Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma.

Authors:  Yu-Chiao Yi; Shih-Chi Wang; Chun-Chin Chao; Chia-Ling Su; Yao-Ling Lee; Ling-Yun Chen
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  RNA-binding IMPs promote cell adhesion and invadopodia formation.

Authors:  Jonas Vikesaa; Thomas V O Hansen; Lars Jønson; Rehannah Borup; Ulla M Wewer; Jan Christiansen; Finn C Nielsen
Journal:  EMBO J       Date:  2006-03-16       Impact factor: 11.598

5.  IMP1 3' UTR shortening enhances metastatic burden in colorectal cancer.

Authors:  Sarah F Andres; Kathy N Williams; Jacqueline B Plesset; Jeffrey J Headd; Rei Mizuno; Priya Chatterji; Ashley A Lento; Andres J Klein-Szanto; Rosemarie Mick; Kathryn E Hamilton; Anil K Rustgi
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

6.  p62 Expression in primary carcinomas of the digestive system.

Authors:  Hong-Liu Qian; Xuan-Xian Peng; Shou-Hui Chen; Hui-Ming Ye; Jing-Hua Qiu
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

7.  IGF2BP1: a novel binding protein of p38 MAPK.

Authors:  Jacob Rini; Moorthy Anbalagan
Journal:  Mol Cell Biochem       Date:  2017-05-11       Impact factor: 3.396

8.  IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.

Authors:  Perry S Mongroo; Felicite K Noubissi; Miriam Cuatrecasas; Jiri Kalabis; Catrina E King; Cameron N Johnstone; Mark J Bowser; Antoni Castells; Vladimir S Spiegelman; Anil K Rustgi
Journal:  Cancer Res       Date:  2011-01-20       Impact factor: 12.701

Review 9.  Autoantibodies to tumor-associated antigens: reporters from the immune system.

Authors:  Eng M Tan; Jianying Zhang
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

10.  Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells.

Authors:  Wei Gu; Amber L Wells; Feng Pan; Robert H Singer
Journal:  Mol Cell Biol       Date:  2008-05-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.